<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20060310153337+01'00'</creation_date><modification_date>D:20070920103615+02'00'</modification_date><initial_authorization>True</initial_authorization><pdf_file>EU-1-01-178_h_a_dec_0.pdf</pdf_file></head><body><section><header n="1">1</header></section><section><header>en</header><p> commission of the european communities</p><p>brussels, 29/03/2001 c(2001) 818</p></section><section><header>commission decision of 29/03/2001 
 granting the marketing authorization for the medicinal 
  
 product for human use, 
  
 &quot;targretin - bexarotene&quot;</header><p> (text with eea relevance)</p><p>only the english text is authentic.</p><p>
 2</p></section><section><header>commission decision of 29/03/2001 
 granting the marketing authorization for the medicinal 
  
 product for human use, 
  
 &quot;targretin - bexarotene&quot;</header><p> (text with eea relevance)</p><p>the commission of the european communities,</p><p>
 having regard to the treaty establishing the european community,</p><p> 
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down community 
 procedures for the authorization and supervision of medicinal products for human and veterinary use 
 and establishing a european agency for the evaluation of medicinal products
 1, and in particular article 10(1) and (2) thereof,</p><p>
 having regard to the application submitted by ligand pharmaceuticals uk ltd, on 17</p><p>december 
 1999, under article 4(1) of regulation (eec) no 2309/93, concerning the medicinal product, 
 &quot;targretin - bexarotene&quot;, 
 having regard to the opinion of 16</p><p>november 2000 of the european agency for the evaluation of 
 medicinal products, formulated by the committee for proprietary medicinal products,</p><p>
 whereas:</p><p>
 (1) the medicinal product, &quot;targretin - bexarotene&quot;, complies with the requirements 
 of council directives 65/65/eec
 2, 75/318/eec3 and 75/319/eec4, as last amended by directive 93/39/eec
 5; (2)</p><p>the measures provided for in this decision are in accordance with the opinion of the 
 standing committee on medicinal products for human use,</p><p> 1 oj no l 214, 24. 8. 1993, p. 1. 2 oj no 22, 9.2.1965, p. 369/65. 3 oj no l 147, 9.6.1975, p. 1. 4 oj no l 147, 9.6.1975, p. 13. 5 oj no l 214, 24.8.1993, p. 22. 3 has adopted this decision:</p><p>article 1</p><p>the marketing authorization referred to in article 3 of regulation (eec) no 2309/93 is hereby granted in respect of the medicinal product: &quot;targretin - bexarotene&quot; whose characteristics are 
 summarized in annex i hereto. this medicinal product shall be entered in the community register of 
 medicinal products under the number:</p><p>
 eu/1/01/178/001 
 targretin - capsule soft - 75 mg - oral use - 1 bottle (hdpe) with 100 soft 
 capsules</p><p>
 article 2</p><p>the marketing authorization concerning the medicinal product referred to in article 1 shall be subject to compliance with all the conditions, particularly those relating to manufacture and/or importation, 
 control and issue referred to in annex ii.</p><p>
 article 3</p><p>the labelling and package leaflet concerning the medicinal product referred to in article 1 shall conform to annex iii.</p><p>
 article 4</p><p>the period of validity of the authorization issued shall be five years from the date of notification of this decision. it shall be renewable under the conditions laid down in article 13(1) of regulation 
 (eec) no 2309/93.</p><p>
 article 5</p><p>this decision is addressed to ligand pharmaceuticals uk ltd, 2 kings hill avenue, west malling, kent me19 4aq, united kingdom.</p><p>
 done at brussels, 29/03/2001</p><p>for the commission</p><p>
 erkki liikanen 
 member of the commision</p></section></body></xml>